Guggenheim Initiates Coverage On Syndax Pharmaceuticals with Buy Rating, Announces Price Target of $40
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Michael Schmidt has initiated coverage on Syndax Pharmaceuticals with a Buy rating and a price target of $40.
July 11, 2023 | 8:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syndax Pharmaceuticals has been initiated with a Buy rating by Guggenheim, with a price target of $40.
The initiation of coverage by Guggenheim with a Buy rating and a price target of $40 indicates a positive outlook for Syndax Pharmaceuticals. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100